


RAVE LITE

Simplified and Accessible Solution for Phase I and Phase IV Trials.




Rave Lite

Rave Lite is a cost effective and focused offering of Rave EDC that supports data capture, data management, and basic data analysis for Phase I, Phase IV, and Feasibility and Post-Market studies for Med Device.

Feasibility and Post-Market studies for Med Device



Recognized as the industry leader in Everest Group's 2024 Peak Matrix Life Sciences Electronic Data Capture.



Rave Lite Benefits

Pay Only for What You Need

Invest in technology designed to meet varying requirements. Medidata provides expert solutions, customized for each trial, delivered when and how they're needed.



Streamline Study Build

Build studies faster and more accurately using a pre-configured, pre-validated, and accelerated implementation.



Affordable Scalability, Superior Functionality

Benefit from Rave EDC's essential capabilities for your unique trial needs. Medidata can scale and pivot as your studies grow.




Differentiators and Advantages

Quick study build



Limited custom functions



Experience Accelerated Study Timelines



1 MONTH FASTER STUDY BUILD

When using Medidata

Professional Services¹



CONDUCTING STUDIES

5 MONTHS FASTER



products²

When using multiple

TO DATABASE LOCK

When using multiple

products³

The Medidata Advantage The world's leading biopharmaceutical and clinical

research organizations choose Medidata because they trust our unparalleled experience and expertise in providing clinical trial technologies to over 35,000 studies

with over 10 million patients and healthy volunteers. Rave Lite offers a consistent experience without sacrificing the advanced power of Rave EDC. Rave Lite is a simplified offering of Rave EDC that is meeting an unmet need in the market for an option of an EDC with focused

functionality and needs for your Phase I, Phase IV, and Feasibility and Post-Market studies for Med Device. Users can execute with agility, work with the cleanest data, easily scale when needed, and gain confidence that

no matter the size or complexity of your trial, Medidata provides a cost-effective offering to meet your needs.

³ Analysis of difference in median LPLV to DBL time for EDC + at least one additional product vs. EDC only studies

¹ Analysis of difference in median build time vs. matched studies not using PS (p<0.05); Reduction of 30 days ² Analysis of difference in median FPI to I PI V time for FDC + at least one additional product vs. FDC only studies (p<0.05).